The growth of Viagra and its effect on the pharmaceutical landscape presents a complicated question for investors. While the initial sales data were remarkable, the intellectual property has lapsed, leading to a wave of copycat alternatives that are reducing profit. In addition, the sector is facing issues related to aging trends and evolving healt